Publications by authors named "Benjamin A Derman"

Claim this Profile
T
The role of maintenance therapy and its cessation in patients with multiple myeloma.
Abigail P Sneider, Benjamin A Derman

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series.
Varsha Swamy, Kaitlin Kelly, Jay L Koyner, Benjamin A Derman, Marco Bonilla

Kidney Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?
Benjamin A Derman

Hematology Am Soc Hematol Educ Program· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.
Tadeusz Kubicki, Benjamin A Derman, Jennifer H Cooperrider, Anna Puła, David Barnidge

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy.
Jennifer H Cooperrider, Benjamin A Derman

Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.
Jennifer H Cooperrider, Diren Arda Karaoglu, Tadeusz Kubicki, Can Rui Jiang, Ella Postich, Benjamin A Derman

Leukemia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical applications of mass spectrometry in multiple myeloma.
Benjamin A Derman, Andrew J Yee

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Benjamin A Derman, Jennifer Cooperrider, Anna Pula, Heidi Simmons, Tadeusz Kubicki

Hemasphere· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Kaitlin Kelly, Jennifer H Cooperrider, Michael R Bishop, Satyajit Kosuri, Andrzej Jakubowiak, Benjamin A Derman

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.
Ola Landgren, Noa Biran, Elizabeth K O'Donnell, Joseph Mikhael, Katja C Weisel, Benjamin A Derman

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
Heather T Morgan, Benjamin A Derman, Hong Ma, Shaji K Kumar

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
David Barnidge, Dhananjay Sakrikar, Tadeusz Kubicki, Benjamin A Derman, Andrzej J Jakubowiak

J Appl Lab Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Benjamin A Derman

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.
Tyra K Grischke, Jennifer H Cooperrider, Anna Pula, Abigail Sneider, Samuel Yates, Benjamin A Derman

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Bei Wang, Benjamin A Derman, Madina Sukhanova, Daniel Appelbaum, John Cursio

Blood Neoplasia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma.
Marcus Marable, Kaitlin Kelly, Jennifer H Cooperrider, Andrzej Jakubowiak, Benjamin A Derman

EJHaem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Access to T-Cell Therapies in Multiple Myeloma.
Benjamin A Derman

Clin Lymphoma Myeloma Leuk· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Benjamin A Derman, Ajay Major, Jennifer Cooperrider, Ken Jiang, Aubrianna Ramsland

Blood Cancer J· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.
Kashyap Padmaraju, Kaitlin Kelly, Andrzej J Jakubowiak, Benjamin A Derman

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Benjamin A Derman

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.
Samuel J Yates, John F Cursio, Andrew Artz, Keriann Kordas, Michael R Bishop, Benjamin A Derman

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels W C J van de Donk, Xavier Leleu, Benjamin A Derman

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study.
Benjamin A Derman, Meaghan Roach, Dee Lin, Bingcao Wu, Richard Murphy

Curr Med Res Opin· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.
Tadeusz Kubicki, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Benjamin A Derman

Pol Arch Intern Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Benjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David E Avigan, Murtuza Rampurwala

Blood Cancer J· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis